RECURRENT GASTRIC CARCINOMA
Clinical trials for RECURRENT GASTRIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GASTRIC CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT GASTRIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers: drug targets DNA repair weakness
Disease control OngoingThis phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …
Matched conditions: RECURRENT GASTRIC CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Matched conditions: RECURRENT GASTRIC CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC